Document is current
Any future updates will be listed below
-
Authors
Meindl, Maria
Zatcepin, Artem
Gnörich, Johannes
Scheifele, Maximilian
Zaganjori, Mirlind
Groß, Mattes
Lindner, Simon
Schaefer, Rebecca
Simmet, Marcel
Roemer, Sebastian
Katzdobler, Sabrina
Levin, Johannes
Höglinger, Günter
Bischof, Ann-Cathrin
Barthel, Henryk
Sabri, Osama
Bartenstein, Peter
Saller, Thomas
Franzmeier, Nicolai
Ziegler, Sibylle
Brendel, Matthias
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EK1605A HitTau)
Deutsche Forschungsgemeinschaft (EXC 2145 SyNergy – ID 390857198))
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 15 September 2023
Accepted: 1 May 2024
First Online: 8 May 2024
Declarations
:
: G.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). O.S. receives research support from LMI. M.B. received speaker honoraria from GE healthcare and LMI and is an advisor of LMI. All other authors do not report a conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the LMU Munich (approval IDs 21–0170, 17–569 and 19–022).
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) , , and .
